Is It Time for New Thinking About High-Density Lipoprotein?

Is It Time for New Thinking About High-Density Lipoprotein? Editorial Is It Time for New Thinking About High-Density Lipoprotein? Christian M. Madsen, Børge G. Nordestgaard he perception of high-density lipoprotein (HDL) choles- mortality with high HDL cholesterol because neither cardio- Tterol as the good cholesterol that protects against athero- vascular nor cancer mortality was increased with high HDL sclerotic cardiovascular disease (ASCVD) has persisted for cholesterol. The main strength of the study is the large num- decades based largely on the countless observational studies ber of included individuals from the general population with showing high risk of ASCVD in individuals with low concen- long-term follow-up. The main limitations include the inher- trations of HDL cholesterol. The notion has been the higher ent inability of observational studies to address the question the better and the faith in HDL cholesterol–elevating drugs of causality and the lack of included information on additional as a new treatment option for ASCVD so great, that >70 000 lipid biomarkers, such as triglycerides, which are inversely patients worldwide have been randomized in phase III out- associated with HDL cholesterol. Two main questions arise from this and the recent similar come trials with the 4 major cholesteryl ester transfer pro- 2–5 14–16 tein inhibitors. Cholesteryl ester http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis, Thrombosis, and Vascular Biology Wolters Kluwer Health

Is It Time for New Thinking About High-Density Lipoprotein?

Loading next page...
 
/lp/wolters_kluwer/is-it-time-for-new-thinking-about-high-density-lipoprotein-Ht25N4R2BP
Publisher
Wolters Kluwer
Copyright
© 2018 American Heart Association, Inc.
ISSN
1079-5642
eISSN
1524-4636
D.O.I.
10.1161/ATVBAHA.118.310727
Publisher site
See Article on Publisher Site

Abstract

Editorial Is It Time for New Thinking About High-Density Lipoprotein? Christian M. Madsen, Børge G. Nordestgaard he perception of high-density lipoprotein (HDL) choles- mortality with high HDL cholesterol because neither cardio- Tterol as the good cholesterol that protects against athero- vascular nor cancer mortality was increased with high HDL sclerotic cardiovascular disease (ASCVD) has persisted for cholesterol. The main strength of the study is the large num- decades based largely on the countless observational studies ber of included individuals from the general population with showing high risk of ASCVD in individuals with low concen- long-term follow-up. The main limitations include the inher- trations of HDL cholesterol. The notion has been the higher ent inability of observational studies to address the question the better and the faith in HDL cholesterol–elevating drugs of causality and the lack of included information on additional as a new treatment option for ASCVD so great, that >70 000 lipid biomarkers, such as triglycerides, which are inversely patients worldwide have been randomized in phase III out- associated with HDL cholesterol. Two main questions arise from this and the recent similar come trials with the 4 major cholesteryl ester transfer pro- 2–5 14–16 tein inhibitors. Cholesteryl ester

Journal

Arteriosclerosis, Thrombosis, and Vascular BiologyWolters Kluwer Health

Published: Mar 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off